

# ForPatients

by Roche

Skin Cancer

## A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

**Trial Status**  
Completed

**Trial Runs In**  
6 Countries

**Trial Identifier**  
NCT04551352 2020-000793-18  
BP42169

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or are non-amenable to SOC. This study will include an initial single participant dose-escalation part one followed by a multiple participant dose-escalation part two with the possibility of expansion.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT04551352 2020-000793-18 BP42169**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---